Literature DB >> 3910224

Ovarian trials at the Royal Marsden.

E Wiltshaw.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 3910224     DOI： 10.1016/0305-7372(85)90020-9

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  24 in total

Review 1.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

2.  Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck.

Authors:  S El-Sayed; R P Symonds; A G Robertson; J Paul; J McGarva
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Towards an assessment of toxicity in the treatment of ovarian cancer.

Authors:  L Dones; E Wiltshaw; B G Birkhead; R R Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay.

Authors:  M G Daidone; R Silvestrini; N Zaffaroni; E Grignolio; F Landoni
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma.

Authors:  C J Twelves; C M Ash; D W Miles; D G Thomas; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Phase I study of oxaliplatin in patients with advanced cancer.

Authors:  J M Extra; M Espie; F Calvo; C Ferme; L Mignot; M Marty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.

Authors:  G Los; L Tuyt; M van Vugt; J Schornagel; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.

Authors:  G Los; E M Verdegaal; P H Mutsaers; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.